VCYT News and Press, Veracyte Inc. From 11/07/23

2023-11-07 20:57:10 ET Veracyte, Inc. (VCYT) Q3 2023 Earnings Conference Call November 07, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial O...

2023-11-07 16:23:47 ET More on Veracyte Veracyte: Testing Numbers Stretching Higher But Valuations Uncertain Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracyte Financial information for Veracyte For further details s...

Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023. “I am please...

Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. Veracyte, Inc . (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its h...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Veracyte Inc. (VCYT) is expected to report $-0.16 for Q3 2023

Veracyte, Inc . (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 15, at 3:00 p.m. Eastern Time. A live audio webcast of the company’s presentations wi...

Two abstracts show the potential for using Veracyte’s tools to characterize the tumor microenvironment Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San ...

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, November 7, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business updat...

Two studies highlight the value of adding Envisia results to standard-of-care procedures for identifying patients at increased risk of progressive disease Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annua...